SCHEMBL7235256

SCHEMBL7235256

COc1cccc(OC(F)(F)F)c1-c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNK3 O14649 1/20 0.47
KCNK9 Q9NPC2 1/20 0.47
FABP3 P05413 1/20 0.43
FABP4 P15090 1/20 0.43
FABP5 Q01469 1/20 0.43
AR P10275 1/20 0.43
PDK2 Q15119 1/20 0.43
PTPN5 P54829 1/20 0.42
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA4 P22748 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41
HTR1A P08908 2/20 0.40
HTR7 P34969 2/20 0.40
SYK P43405 1/20 0.39
SCN9A Q15858 4/20 0.39
FGFR1 P11362 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL355567 0.84 CA1 (0.57) FABP3FABP4FABP5ARCA12
Phosphine SCHEMBL27891320 0.82 CA1 (0.55) FABP3FABP4FABP5ARCA12
Benzene SCHEMBL28977457 0.82 CA1 (0.55) FABP3FABP4FABP5ARCA12
Water SCHEMBL28136778 0.82 CA1 (0.55) FABP3FABP4FABP5ARCA12
Hydrochloric Acid SCHEMBL30310852 0.82 CA1 (0.55) FABP3FABP4FABP5ARCA12
SCHEMBL29217584 0.79 FABP4 (0.53) FABP3FABP4FABP5ARCA12
SCHEMBL8592250 0.79 CA1 (0.50) FABP3FABP4FABP5CA12CA1
SCHEMBL29435933 0.78 CA1 (0.62) KCNK3KCNK9PDK2CA12CA1
SCHEMBL625622 0.78 CA1 (0.62) KCNK3KCNK9PDK2CA12CA1
SCHEMBL1043306 0.78 GRIA1 (0.41) KCNK3KCNK9PTPN5SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6645939-B1 Very late antigen-4 (VLA) integrin antagonists; antiallergens, antiasthmatics, and antiinflammatory agents; multiple sclerosis, autoimmune disease treatment MERCK & CO., INC. 2003-11-11 US disclosed